

Identifying loci affecting trait variability and detecting interactions in genome-wide association studies

Alexander I. Young^{1,2*}, Fabian L. Wauthier^{1,3}, Peter Donnelly^{1,3*}

1) Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, U.K.;

2) Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, U.K.

3) Department of Statistics, University of Oxford, Oxford, U.K..

* To whom correspondence should be addressed: donnelly@well.ox.ac.uk or alexander.young@bdi.ox.ac.uk.

Abstract

Identification of genetic variants with effects on trait variability can provide insights into biological mechanisms that control variation and can identify potential interactions. We propose a two degree-of-freedom joint test for mean and variance effects to identify such variants. We implement the test in a linear mixed model, for which we provide an efficient algorithm and software. To focus on biologically interesting settings, we develop a test for dispersion effects, that is variance effects not driven solely by mean effects when the trait distribution is non-normal. We apply our approach to BMI in the subsample of the UK Biobank with British ancestry ($n \sim 408,000$) and show that our approach can increase power to detect associated loci. We identify and replicate novel associations with significant variance effects that cannot be explained by the non-normality of BMI, and we provide suggestive evidence for a connection between leptin levels and BMI variability.

Introduction

Nearly all GWAS associations have been discovered by testing the simplest additive model¹. There is a longstanding controversy about the importance of departures from the additive model in human genetics². In addition, the extent and nature of interactions between genetic variants and environmental factors remains poorly characterized. The advent of large population-based cohorts, such as the UK Biobank³, will provide large samples of genotyped individuals along with rich lifestyle and environment information. With the right statistical methodology, this will accelerate characterization of the interaction between genes and environment.

The problem of searching for interaction effects is harder than for additive effects in part because the number of possible interaction models grows super-linearly with the number of possible interacting variables⁴. It has been recognised that the variance of a quantitative phenotype differs with genotype at loci involved in interactions^{5,6}. Therefore, one can reduce the search space of possible interaction models by screening genome-wide loci for variance effects.

Interactions involving genetic variants are one cause of a more general phenomenon: genetic effects on phenotypic variability⁷⁻⁹. Control of phenotypic variability, both within and between individual organisms, is a fundamental property of biological systems¹⁰. It is likely that organisms have evolved to suppress certain kinds of variability resulting from developmental processes and environmental stimuli⁷. The understanding of genetic effects on phenotypic variability is poor compared to the understanding of genetic effects on mean trait values⁷, in part because methods for investigating effects on variability are not as well developed.

Most published methods for detecting loci affecting phenotypic variability concentrate on testing for a variance effect alone^{11,12}, even though such loci are also likely to affect the mean of the phenotype. Methods which jointly test for mean and variance effects^{13,14} are not as well developed as those for additive association testing and their implementation in a linear mixed model framework relies on algorithms which scale cubically with sample size^{14,15}, making them impractical to apply to the large sample sizes needed to detect variance effects on complex human traits.

Here we introduce a two degree-of-freedom test for jointly testing mean and variance effects on quantitative traits. If the trait distribution is non-normal, then additive effects at a locus will induce variance effects that are unlikely to be of interest. We show how to account for this and thereby detect variance effects not driven by mean effects. We implement the test in a mixed model framework and develop an algorithm for fitting this model whose computations scale linearly with the sample size. To illustrate application of the method, we analyse BMI in the subsample of the UK Biobank with predominantly British ancestry ($n \sim 408,000$).

Results

Variance models

We introduce a variance effect that is analogous to the additive effect on the mean. Because the variance is always positive, one cannot use a linear model, which is unbounded; instead, we use

a log-linear model. Let $\sigma_g^2 = \text{Var}(Y|G = g)$ be the variance conditional on the allele count at a single nucleotide polymorphism (SNP) G being $g \in \{0,1,2\}$. This model has the form

$$\log(\sigma_g^2) = \mu_v + \alpha_v g,$$

for some constant μ_v and *log-linear variance effect* α_v . We note that, when variance effects are small, log-linear variance effects should be approximately equivalent to the linear variance effects modelled in a previous meta-analysis of variance effects¹². We fit this in a model that also allows for an additive effect on the mean:

$$M_{AV}: Y|G = g \sim N(\mu + \alpha g, \exp(\mu_v + \alpha_v g)),$$

which we call the additive-variance model or ‘AV’ model for short.

To model more complicated relationships between genotype and phenotypic variance, we introduce a ‘general variance’ effect, δ_v , that models non-linear changes in log-variance with genotype:

$$\log(\sigma_g^2) = \mu_v + \alpha_v g + \delta_v (g - 2f)^2,$$

where f is the allele frequency. In the Supplementary Note, we show how these variance models fit into a hierarchy of models for the effect of genotype on phenotype, and we show the connection between the test statistics and the mutual information between genotype and phenotype.

Variance Tests

There is a natural one degree-of-freedom test for a log-linear variance effect, as well as the general two degree-of-freedom test for both a log-linear variance effect and a general variance effect. Cao et al. had previously suggested using the two-degree of freedom variance test, which is very similar to the Bartlett test¹³.

To assess power of the two approaches, we simulated traits affected by a genetic variant (frequency=0.5) with both a log-linear variance effect and a general variance effect (Methods). For the sample size considered ($n=100,000$), the one degree-of-freedom test was more powerful unless the variance of the heterozygote deviated by 2% or more from a log-linear variance model (Supplementary Table 1). We also show in the Supplementary Note that the functional

form of the effect on the log-variance for an interacting locus is linear up to a correction on the order of $O(\alpha_v^2)$.

We therefore propose a test for discovery of loci with mean and variance effects that compares the likelihood of the additive-variance model, M_{AV} , to the likelihood of the null model. We call this the additive-variance (AV) test. Due to reduced degrees of freedom, this test should have improved power over the test proposed by Cao et al.¹³ unless the variance of the heterozygote deviates substantially from a log-linear model.

We note that dominance (a non-linear relationship between phenotypic means and allele counts) could potentially induce spurious variance effect estimates from a model that assumes a linear relationship between allele counts and phenotypic means. We recommend to check for this for variants displaying evidence for a variance effect under the AV model by also fitting a model including a dominance effect (Supplementary Note).

Non-normality and variance effects

The models and test statistics so far have been derived under an assumption of normality. When the phenotype distribution is non-normal, the null distribution of the variance test statistic is improperly calibrated¹⁶. Inverse normal transformation of the phenotype can be used to ensure that the null distribution of the variance test statistic is properly calibrated. However, there is a relationship between the mean and the variance of any non-normal distribution. This implies that, when trait values follow a non-normal distribution, any genetic variant that affects the mean of the trait will also affect the variance of the trait. This phenomenon can be seen in genome-wide estimated mean and variance effects on BMI taken from summary statistics provided by the GIANT consortium^{12,17} (Supplementary Figure 3). This kind of variance effect is unlikely to be of direct interest, and is not indicative of an interaction effect.

Variance effects driven by a mean-variance relation can, in theory, be removed by a variance stabilizing transformation if the mean-variance relation is known. However, it turns out that variance effects due to a mean-variance relation are not, in general, removed by inverse-normal transformation.

We introduce “dispersion effects”, which are effects on phenotypic variance that are independent of the general mean-variance relation of the phenotype distribution, implying that they are insensitive to transformation of the phenotype (Methods and Supplementary Note). We show that, when additive effects are small, there is an approximately linear relationship between the additive effect (α_l), the log-linear variance effect (α_{vl}), and the dispersion effect (d_l) at each locus l (Supplementary Note):

$$\alpha_{vl} \approx r_{av}\alpha_l + d_l,$$

where r_{av} parameterizes the expected log-linear variance effect due to the general mean-variance relation and can be estimated from genome-wide regression of log-linear variance effect estimates on additive effect estimates (Methods). Given r_{av} , dispersion effects are estimated by $\hat{d}_l = \hat{\alpha}_{vl} - r_{av}\hat{\alpha}_l$.

The heteroskedastic linear mixed model

Linear mixed models can be used to model the effects of many genome-wide SNPs on the mean of a trait^{18,19}. The effects are modelled as random effects, typically drawn from a normal distribution. Depending on how the SNPs are selected, linear mixed models can increase power and/or control for population structure and relatedness in genome-wide association studies¹⁹. The heteroskedastic linear mixed model (HLMM) is a generalisation of the standard mixed model that also models the effect of a set of variables on the residual variance of a trait. While such models have been proposed before¹⁵, existing algorithms for them scale with the cube of the sample size¹⁵, making them impractical for large samples. We give an algorithm for fitting the model that scales linearly when the number of random effects is fixed (Methods).

While the heteroskedastic linear mixed model offers a potential gain in both power and robustness, it comes at a computational cost. In some settings, it will be appropriate to simply fit the heteroskedastic linear model, which is very fast. We provide software for fitting both the mixed and linear versions of the heteroskedastic model (see Code Availability).

Simulation of inference on a non-normal phenotype

To demonstrate inference on a non-normal phenotype, we simulated 10 non-normal phenotypes ($n=150,000$) using a Gamma Model (Methods). In the Gamma Model, every SNP

with an additive effect on the untransformed phenotype also has a linear effect on the phenotypic variance. For each phenotype, out of 22,000 simulated SNPs with varying frequencies, 1000 were chosen to have additive effects on the phenotype, with 10% of the phenotypic variance explained by the combined additive effects. One of the 1000 SNPs with additive effects was chosen to have a log-linear dispersion effect of 0.05 as well as an additive effect in the same direction as the dispersion effect. An inverse-normal transformation was performed on the phenotypes before analysis.

Inference of additive and AV models was performed by maximum likelihood (Supplementary Note), and dispersion effects were inferred (Methods). The Kolmogorov-Smirnov (K.S.) test was used to detect deviations from theoretical null distributions. Test statistics were combined across the 10 independent phenotypes for the K.S. tests. For the null SNPs, we found no evidence for deviations from the theoretical null distributions for all of the test statistics examined: additive ($n=210,000$, $D=0.0015$, $p=0.23$), log-linear variance ($n=210,000$, $D=0.0017$, $p=0.58$), AV ($n=210,000$, $D=8 \times 10^{-4}$, $p=1.00$), and dispersion ($n=210,000$, $D=0.0019$, $p=0.60$).

For the 999 SNPs with additive effects on the non-normal phenotype, but no dispersion effect, the log-linear variance test statistics showed strong evidence for deviation from the null ($n=9,990$, $D=0.11$, $p < 2.2 \times 10^{-16}$), with a mean log-likelihood ratio test statistic 56% larger than would be expected under the null. However, there was no evidence that dispersion effect test statistics deviated from the null ($n=9,990$, $D=0.0078$, $p=0.58$). In contrast, for the locus with a dispersion effect, the average p-value for a dispersion effect was 6.8×10^{-11} . This demonstrates that our method is able to powerfully distinguish between loci that have variance effects due to a general mean-variance relation, and loci that have dispersion effects.

To simulate inference with the HLMM, we modelled random effects for the top 1000 SNPs ranked by additive test statistic for each simulation. For the null SNPs, we found no evidence for deviation from theoretical null distributions for additive test statistics ($n=210,000$, $D=0.0019$, $p=0.43$). However, we found evidence for slight deflation of log-linear variance (mean=0.984, $p=3.0 \times 10^{-5}$ from K.S. test) and dispersion test statistics (mean=0.990, $p=0.008$). While there may be a very slight deflation of variance test statistics for the null SNPs, this does not imply there is reduced power for causal SNPs.

Compared to the non-mixed model, the additive Chi-Squared statistic was 9.5% higher on average for causal SNPs without dispersion effects, and the log-linear variance statistics were 20.3% lower. For the SNP with a true dispersion effect, the dispersion Chi-Squared test statistic

was 14.6% higher on average compared to the non-mixed model analysis. This shows that modelling random effects of SNPs can increase power to detect loci with additive and dispersion effects.

Application to BMI in the UK Biobank

We analysed the subsample of the UK Biobank with predominantly white British ancestry as defined by the UK Biobank quality control process²⁰. We applied an inverse-normal transformation to BMI, and adjusted for age, sex and 40 principal components (Methods). After sample quality control (Methods), there were 408,250 individuals with both genotype and BMI data. We split the sample into two: an ‘unrelated’ subsample (n=276,415), with no pairs related at the third degree or higher; and the complementary ‘related’ subsample (n=131,835), which contains all third degree or closer relative pairs. We did this to demonstrate two different uses of the mixed model: to increase power in a homogeneous, unrelated sample, and to control for relatedness. We selected 500 SNPs to model random effects for the unrelated sample and 1000 SNPs for the related sample (Methods). We then combined the additive and log-linear variance effects from the two subsamples to give single estimates of additive and log-linear variance effects for each SNP (Supplementary Table 2).

To visualise the genome-wide results of fitting the AV model, we introduce the ‘Manhattan Sunset’ plot (**Figure 2**), which displays additive and log-linear variance test statistics stacked on top of each other, highlighting any loci with evidence for variance effects. We note that many SNPs in the MHC region on chromosome 6 appear to have both additive and variance effects on BMI (Figure 2). Due to its complexity, we do not pursue further analysis of this region here.

We determined that a locus was significant if its p-value for the AV test was below the accepted conventional level for genome-wide significance, namely 5×10^{-8} (Methods). Out of 328 loci that are genome-wide significant under either the additive or AV tests (Supplementary Table 3), 48 loci have a smaller p-value from the AV test than from the additive test, including the *FTO* locus. Most loci have a smaller p-value from the additive test, however, and 56 loci that are genome-wide significant under the additive test are not genome-wide significant under the AV test.

While there may be a slight loss of power for most associated loci, for loci with substantial dispersion effects there is likely to be a gain in power. There were 15 loci that were genome-wide significant under the AV test and not under the additive test, some of which showed evidence for dispersion effects, as we outline below.

Evidence for dispersion effects

Untransformed BMI is non-normal, so variance effects may be due to a general mean-variance relation that has not been removed by inverse normal transformation. To move beyond this, we estimated dispersion effects for all test SNPs genome-wide (Methods). We inferred that, for inverse-normally transformed BMI, $r_{av} \approx 0.135$ (Figure 3) (Methods). While the genome-wide additive and log-linear variance test statistics show similar patterns of deviation from the null, the dispersion test statistics follow a different pattern (Figure 4). This is further evidence that the component of the variance test statistics driven by mean effects has been largely removed from the dispersion test statistics. The systematic excess, relative to the null, of large test statistics in the right-hand half of the dispersion quantile-quantile plot (Figure 4) shows that there are likely to be many SNPs with real dispersion effects.

One locus reached genome-wide significance for a dispersion effect, rs900400 ($p=1.2 \times 10^{-8}$, Figure 5). Furthermore, some of the loci with strong evidence under the AV model display evidence of dispersion effects: we list those loci with $p < 10^{-3}$ for a dispersion effect and $p < 5 \times 10^{-8}$ under the AV test in Table 1.

There are three loci in this list (around rs1538749, rs1801282, and rs900400) not previously associated with BMI at genome-wide significance levels, though rs1538749 and rs900400 have been associated with other obesity-related phenotypes at genome-wide significance levels (including hip circumference and waist-hip ratio for rs1538749 and waist circumference and waist-hip ratio for rs900400)²¹. Of the other loci in the table, there are two known loci with strong effects on BMI (*GIPR* and *FTO*), a synonymous codon variant (rs2303223) in *ZNF668* in strong linkage-disequilibrium ($r^2=0.993$) with a previously identified missense variant (rs749670) in *ZNF646*²², and a variant at the *TCF7L2* locus (rs10787472), which contains variants with known strong effects on type-II diabetes risk.

Using results from GIANT meta-analyses^{12,17}, we examined whether additive and variance effects replicated. We replicated the variance effect for rs900400 ($p=1.1 \times 10^{-3}$) (Table 1). The estimated additive effect for rs900400 is so weak that it is consistent with zero in both our data ($p=0.12$) and the GIANT meta-analysis ($p=0.18$). The C allele of SNP rs900400 has been associated with lower birth weight^{23,24}, and the locus provides the strongest association genome-wide for this phenotype. By using self-reported birth weight data from UK Biobank, we showed that the variance effect of rs900400 was not mediated through its effect on birth weight

(Methods). The SNP rs900400 also shows genome-wide significant association with expression of *TIPARP* in adipocytes²⁵, and with age at menarche²⁶.

For rs1801282, the additive effect we observed replicated in the GIANT meta-analysis ($p=4.2 \times 10^{-7}$). The estimated variance effect is consistent between our analysis (0.022) and the GIANT meta-analysis (0.015), but it does not quite reach statistical significance in the GIANT meta-analysis ($p=0.084$). The SNP rs1801282 is a missense variant in the gene *PPARG*. *PPARG* is involved in fatty acid storage and glucose metabolism, and is a target for a class of type 2 diabetes drugs (Thiazolidinediones or TZDs). The minor G allele has been repeatedly associated with reduced type-II diabetes risk²⁷. We found that the minor G allele is also associated with increased BMI and increased variability in BMI. The additive effects on type 2 diabetes and BMI are similar to the action of TZDs, which treat type 2 diabetes but have been found to cause fat gain²⁸. We did not find evidence that the variance effect is mediated through an interaction with type-II diabetes status ($p=0.58$) (Methods).

For rs1538749, the additive effect was consistent but not quite statistically significant ($p=0.097$) in GIANT meta-analysis. The variance effect did not replicate, with an effect estimate close to zero ($p=0.84$).

We found that nearly half of the previously identified variance effect of the *FTO* risk allele¹² (rs1421085) (0.027 per risk allele) can be explained by its additive effect, with a much smaller estimated dispersion effect (0.017 per risk allele).

Putative gene-by-environment interactions

By using a previously published approach to test jointly for interactions between lifestyle and/or environmental variables and variation at the *FTO* locus²⁹, we tested for interactions between the SNPs in Table 1 and diet, physical activity, sleep, sleep duration, TV watching, frequency of alcohol consumption, and socio-economic status (Townsend Deprivation Index) (Methods). The results of fitting these interaction models are in Supplementary Table 4. Here, we report interactions with $p < 0.005$, except for SNP rs1421085 (*FTO*), on which we have previously reported²⁹.

The only SNP other than rs1421085 (*FTO*) with strong evidence for a specific gene-by-environment interaction was rs900400. We found evidence for an interaction with physical activity ($p=5.0 \times 10^{-5}$). There was also suggestive evidence for an interaction with diet ($p=6.2 \times 10^{-5}$).

³). The results suggest that the variability increasing allele may enhance the effect of physical activity and diet variation on BMI. Modelling the interactions reduced the estimated variance effect of rs900400 from 0.0200 to 0.0185, indicating the modelled interactions do not explain all of the variance effect of rs900400. In contrast, the modelled interactions reduced the variance effect of rs141085 (*FTO*) from 0.027 to 0.018, indicating that the interactions explain a substantial fraction of the variance effect of the *FTO* locus.

Leptin and BMI dispersion effects

The T allele of SNP rs900400 has also been associated with higher levels of circulating leptin after adjusting for BMI³⁰. To investigate whether there might be a more general connection between leptin levels and BMI variability, we next asked whether SNPs associated with changes in leptin levels tended to be associated with BMI variability. Specifically, we took the top 100 lead SNPs from independent loci with evidence for effects on leptin levels adjusted for BMI³⁰ and compared their estimated effects on leptin adjusted for BMI with their estimated BMI dispersion effects. We observed a small but significant linear relationship between the effect of the SNP on leptin adjusted for BMI and on BMI dispersion: we estimate that a SNP that increases leptin levels by 1SD per allele would have an expected dispersion effect on BMI of 0.032 ($p = 0.026$, Methods and Supplementary Figure 4). These results suggest, by a Mendelian Randomisation argument, that there may be a connection between leptin and BMI variability.

Discussion

We have introduced a new framework for association testing which extends widely-used additive tests by testing both for an linear change in phenotypic mean (exactly as in additive tests) and for a log-linear change in phenotypic variance. A new visualization tool, the Manhattan Sunset Plot, provides a genome-wide picture of evidence for both additive and log-linear variance effects.

When applied to GWAS and related studies, this approach (i) can be more powerful for discovery of associated loci, and (ii) can specifically identify loci with effects on phenotypic variability. We have demonstrated both of these potential advantages through simulations and application to BMI in the UK Biobank.

Mixed model approaches have several advantages¹⁹. The test we propose can be performed in the heteroskedastic linear mixed model (HLMM), for which we provide an algorithm that scales linearly with sample size for a fixed number of random effects. We have demonstrated in

simulations that our method has increased power over other joint tests for mean and variance effects due to both 1) reduction in degrees of freedom of variance test statistic and 2) reduction in signal to noise ratio from modelling random effects of SNPs with evidence for association.

When multiple haplotypes with different phenotypic effects are present in the region of a SNP, this can generate association between genotype and phenotypic variance at the SNP⁸. While detailed investigation of this phenomenon is beyond the scope of this paper, it might explain some of the additive and variance effects of SNPs in the MHC region. However, this phenomenon is unlikely to explain the variance effect of rs900400, since it occurs between two close recombination hotspots, or the variance effects of the other SNPs in Table 1, since the SNPs are not in linkage disequilibrium ($r^2 < 0.01$) with other SNPs with strong evidence for additive effects (Methods).

Variance effects that are explained by a general mean-variance relation are unlikely to reflect interactions or other biologically meaningful phenomena. We developed a method that is able to identify when a SNP has a variance effect beyond that which can be explained by a general mean-variance relation, which we term a 'dispersion effect'. As one application, we showed that around half of the reported effect of the FTO locus on BMI variability¹² is explained by a general mean-variance relation, and so may not be biologically interesting.

While only rs900400 showed genome-wide significant evidence for a dispersion effect, six other SNPs that were genome-wide significant under the AV test showed some evidence for a dispersion effect (Table 1). More generally, the genome-wide test statistics showed an excess of large dispersion effect estimates (Figure 4), implying that these effects are prevalent and may be worthy of further investigation. It has been previously observed that rs900400 affects leptin levels³⁰ and we found suggestive evidence for a more general connection between leptin and BMI variability.

The statistical testing framework we have developed can be applied to many other traits, enabling discovery of genetic factors affecting trait variability. Beyond intrinsic biological interest in factors determining trait variability, this approach can guide the search for gene-gene and gene-environment interactions. Its application in large population biobanks will enable well-powered studies which increase our understanding of the interactions which influence phenotypic variation in human populations.

Acknowledgements

This work was supported by Wellcome Trust grants 095552/Z/11/Z to PD and Grants 090532/Z/09/Z and 20314/Z/16/Z as core support for the Wellcome Trust Centre for Human Genetics. AY was supported by a Wellcome Trust Doctoral Studentship (099670/Z/12/Z) and by the Li Ka Shing Foundation. We thank J. Marchini for comments on an earlier version of the manuscript.

Author Contributions

AY developed the method, led the application of it to the UK Biobank data, and wrote the paper. FLW was involved in the development and application of the method. PD supervised the research and wrote the paper. All work undertaken by FLW was done while FLW was at University of Oxford.

Competing Financial Interests

P.D. is a founder and director of Genomics PLC, and a partner of Peptide Groove LLP. The remaining authors declare no competing financial interests.

URLs

LD-scores: <https://data.broadinstitute.org/alkesgroup/LDSCORE/>

References

1. Price, A. L., Spencer, C. C. A. & Donnelly, P. Progress and promise in understanding the genetic basis of common diseases. *Proc. R. Soc. B Biol. Sci.* **282**, 20151684 (2015).
2. Hill, W. G., Goddard, M. E. & Visscher, P. M. Data and theory point to mainly additive genetic variance for complex traits. *PLoS Genet.* **4**, e1000008 (2008).
3. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* **12**, e1001779 (2015).
4. Marchini, J., Donnelly, P. & Cardon, L. R. Genome-wide strategies for detecting multiple loci that influence complex diseases. *Nat. Genet.* **37**, 413–417 (2005).
5. Paré, G., Cook, N. R., Ridker, P. M. & Chasman, D. I. On the use of variance per genotype as a tool to identify quantitative trait interaction effects: a report from the Women's Genome Health Study. *PLoS Genet.* **6**, e1000981 (2010).
6. Struchalin, M. V., Dehghan, A., Witteman, J. C., van Duijn, C. & Aulchenko, Y. S. Variance heterogeneity analysis for detection of potentially interacting genetic loci: method and its limitations. *BMC Genet.* **11**, 92 (2010).
7. Hill, W. G. & Mulder, H. a. Genetic analysis of environmental variation. *Genet. Res. (Camb)*. **92**, 381–

- 395 (2010).
8. Forsberg, S. K. G. *et al.* The Multi-allelic Genetic Architecture of a Variance-Heterogeneity Locus for Molybdenum Concentration in Leaves Acts as a Source of Unexplained Additive Genetic Variance. *PLoS Genet.* **11**, 1–24 (2015).
 9. Ivarsdottir, E. V *et al.* Effect of sequence variants on variance in glucose levels predicts type 2 diabetes risk and accounts for heritability. *Nat. Genet.* 1–8 (2017). doi:10.1038/ng.3928
 10. Kitano, H. Biological robustness. *Nat. Rev. Genet.* **5**, 826–837 (2004).
 11. Rönnegård, L. & Valdar, W. Recent developments in statistical methods for detecting genetic loci affecting phenotypic variability. *BMC Genet.* **13**, 63 (2012).
 12. Yang, J. *et al.* FTO genotype is associated with phenotypic variability of body mass index. *Nature* **490**, 267–272 (2012).
 13. Cao, Y., Wei, P., Bailey, M., Kauwe, J. S. K. & Maxwell, T. J. A versatile omnibus test for detecting mean and variance heterogeneity. *Genet. Epidemiol.* **38**, 51–59 (2014).
 14. Cao, Y., Maxwell, T. J. & Wei, P. A Family-Based Joint Test for Mean and Variance Heterogeneity for Quantitative Traits. *Ann. Hum. Genet.* **79**, 46–56 (2015).
 15. Rönnegård, L., Felleki, M., Fikse, F., Mulder, H. A. & Strandberg, E. Genetic heterogeneity of residual variance - estimation of variance components using double hierarchical generalized linear models. *Genet. Sel. Evol.* **42**, 8 (2010).
 16. Box, A. G. E. P. & Box, G. E. P. Non-Normality and Tests on Variances. *Biometrika* **40**, 318–335 (1953).
 17. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).
 18. Zhang, Z. *et al.* Mixed linear model approach adapted for genome-wide association studies. *Nat. Genet.* **42**, 355–60 (2010).
 19. Yang, J., Zaitlen, N. a, Goddard, M. E., Visscher, P. M. & Price, A. L. Advantages and pitfalls in the application of mixed-model association methods. *Nat. Genet.* **46**, 100–6 (2014).
 20. Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv* (2017). doi:10.1101/166298
 21. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).
 22. Turcot, V. *et al.* Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. *Nat. Genet.* **50**, 26–35 (2018).
 23. Horikoshi, M. *et al.* New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. *Nat. Genet.* **45**, 76–82 (2013).
 24. Freathy, R. M. *et al.* Variants in *ADCY5* and near *CCNL1* are associated with fetal growth and birth weight. *Nat. Genet.* **42**, 430–435 (2010).
 25. Hivert, M. F. *et al.* Genetic determinants of adiponectin regulation revealed by pregnancy. *Obesity* **25**, 935–944 (2017).
 26. Perry, J. R. B. *et al.* Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* **514**, 92–97 (2014).

27. Zeggini, E. *et al.* Replication Association Reveals of Genome-Wide in UK Samples Signals Risk Loci for Type 2 Diabetes. *Science (80-.).* **316**, 1336–1341 (2007).
28. Larsen, T. M., Toubro, S. & Astrup, A. PPARgamma agonists in the treatment of type II diabetes: Is increased fatness commensurate with long-term efficacy? *Int. J. Obes.* **27**, 147–161 (2003).
29. Young, A. I., Wauthier, F. & Donnelly, P. Multiple novel gene-by-environment interactions modify the effect of FTO variants on body mass index. *Nat. Commun.* **7**, 1–12 (2016).
30. Kilpeläinen, T. O. *et al.* Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. *Nat. Commun.* **7**, (2016).

Figures




Figure 1 Association signal of additive-variance (AV) test for simulated phenotypes with different parameters. The expected $-\log_{10}(\text{p-value})$ of the AV test for different additive and log-linear variance effects of the test-locus is indicated by shading. Phenotypes were simulated for 100,000 unrelated individuals (Methods). The test locus had frequency 0.5, and the strength of the additive effect is parameterised by the amount of variance explained, h^2 . The log-linear variance effect is indicated on the y-axis and corresponds approximately to the proportional change in phenotypic variance per-allele. We have highlighted two regions of parameter space: the area inside the green lines is where the association signal is stronger under the AV test than under the additive test, and the area inside the yellow lines is where the AV test is genome-wide significant ($p < 5 \times 10^{-8}$) but the additive test is not.




Figure 2 'Manhattan Sunset' plot visualising the genome-wide additive and log-linear variance test statistics for log-BMI. At each locus, the additive χ^2 test statistic is plotted as a blue bar, and the χ^2 test statistic for a log-linear variance effect is added on top of this in red, the combined height of which gives the AV test statistic, the $-\log_{10}(\text{p-values})$ of which are marked on the right-hand y-axis. Test statistics were derived from combining effect estimates from the related and unrelated subsamples of the UK Biobank (Methods). Names of the nearest protein coding genes are indicated for loci that passed genome-wide-significance ($p < 5 \times 10^{-8}$) for the additive-variance test and displayed evidence of a dispersion effect ($p < 1 \times 10^{-3}$) (Table 1). In addition, the MHC region is indicated.




Figure 3 Relationship between additive and log-linear variance effects. Estimated additive (x-axis) and log-linear variance (y-axis) effects on BMI are plotted for all genome-wide SNPs, shaded in proportion to the $-\log_{10}(p)$ -value) for an additive effect, up to a maximum of $-\log_{10}(5 \times 10^{-8})$, the conventional boundary for genome-wide significance. Due to the mean-variance relationship of untransformed BMI, any locus with an additive effect is expected to have a log-linear variance effect, even after inverse-normal transformation. The red line shows the expected log-linear variance effect given a particular additive effect for inverse-normally transformed BMI, where we have inferred this relationship empirically (Methods). Note that SNPs on chromosome 6 were excluded in order to exclude SNPs from the MHC region.




Figure 4 Quantile-Quantile plots for test statistics. We compare the sample quantiles of the additive, log-linear variance, and dispersion test statistics to the theoretical quantiles of the null distribution. Under the null distribution, the test statistics asymptotically follow a Chi-Squared distribution on one degree-of-freedom. Additive test statistics were adjusted for inflation using LD-score regression³¹; log-linear variance and dispersion test statistics were adjusted for inflation using genomic-control (Methods). Note that, due to widespread association in the MHC region (Figure 2), we removed SNPs from chromosome 6 from these plots.




Figure 5 Manhattan plot for dispersion effects. The p-value for a dispersion effect is plotted for each tested SNP, with chromosome indicated on the x-axis. Names of the nearest protein coding genes are indicated for loci that are genome-wide significant ($p < 5 \times 10^{-8}$) under the additive-variance test and have $p < 10^{-3}$ for a dispersion effect (Table 1). Note that SNP rs900400 (*CCNL1*) occurs between two close recombination hotspots, with no other genotyped SNPs in strong linkage disequilibrium with rs900400. In addition, the MHC is highlighted.

Tables

			additive			log-linear variance			AV			dispersion			GIANT additive			GIANT variance			
chr:position	gene(s)	alleles	EAF							p	$\frac{X_v^2}{X_{av}^2}$										
				Est.	S.E.	p	Est.	S.E.	p			Est.	S.E.	p	Est.	S.E.	p				
rs1538749*	1:219,649,865	LPYLALI	A/C	0.45	-0.0083	0.0022	3.9e-04	-0.016	0.0032	9.7e-07	1.1e-08	0.656	-0.015	0.0032	4.8e-06	-0.0063	0.0038	9.7e-02	-0.0012	0.0058	8.4e-01
rs1801282	3:123,931,25	PPARG	G/C	0.12	0.0152	0.0033	2.3e-05	0.022	0.0048	1.8e-05	1.3e-08	0.506	0.020	0.0048	9.8e-05	0.0231	0.0046	4.2e-07	0.0150	0.0085	8.4e-02
rs900400	3:156,798,775	CCNLI	T/C	0.61	0.0037	0.0022	1.2e-01	0.020	0.0032	5.5e-09	1.2e-08	0.933	0.019	0.0032	1.2e-08	0.0054	0.0040	1.8e-01	0.0200	0.0061	1.1e-03
rs10787472	10:114,781,297	TCF7L2	C/A	0.47	-0.0156	0.0022	2.1e-11	-0.015	0.0032	9.0e-06	9.3e-15	0.305	-0.013	0.0032	1.3e-04	-0.0155	0.0031	4.1e-07	-0.0160	0.0057	5.0e-03
rs2303223	16:310,751,75	ZNF668	A/G	0.37	-0.0209	0.0022	2.4e-18	-0.015	0.0032	9.5e-06	1.5e-21	0.204	-0.012	0.0033	3.0e-04	-0.0184	0.0031	3.7e-09	-0.0120	0.0058	3.7e-02
rs1421085	16:538,009,54	FTO	C/T	0.40	0.0746	0.0022	2.0e-217	0.027	0.0032	1.1e-15	8.8e-230	0.061	0.017	0.0032	4.3e-07	0.0813	0.0031	8.8e-151	0.0260	0.0064	5.9e-05
rs10423928	19:461,823,04	GIPR	T/A	0.81	0.0332	0.0027	1.9e-29	0.021	0.0040	5.4e-07	9.4e-34	0.165	0.017	0.0040	7.2e-05	0.0299	0.0052	8.9e-09	0.0150	0.0077	6.0e-02

Table 1 Loci with evidence for dispersion effects. The statistics for loci which were genome-wide significant ($p < 5 \times 10^{-8}$) under a joint test for additive and log-linear variance effects and had $p < 10^{-3}$ for a dispersion effect¹². Additive and log-linear variance effect estimates were derived from combining estimates from the related and unrelated subsamples of the UK Biobank (Methods). Gene names are the nearest protein coding gene. The effects are given per copy of the first allele (per copy of the C-allele if the alleles are given as, for example, C/T) for inverse-normally transformed BMI. The ratio of the log-linear variance test statistic to the additive-variance test statistic is given under $\frac{X_p^2}{X_{av}^2}$. The additive effect and p-value from the GIANT consortium meta-analysis of BMI²¹ and the variance effect from the GIANT meta-analysis of variance effects on BMI¹² are given for external validation. *For rs1538749, we used a proxy, rs11118304, with $r^2 \approx 1$, to obtain relevant summary statistics from the GIANT consortium. EAF: estimated allele frequency.

Code Availability

The software used is freely available under an MIT license at

<https://github.com/AlexTISYoung/hlmm>.

Data Availability

The primary data analysed in this study come from the UK Biobank. Applications for access can be made on the UK Biobank website.

Online Methods

Estimation of dispersion effects

Variation at a locus l has a log-linear dispersion effect d_l on a (not necessarily normal) phenotype Y if $E[Y|G_l = g] = \mu_{lg}$, and

$$\text{Var}(Y|G_l = g) = h(\mu_{lg})\exp(d_l(g - 2f_l)),$$

where f_l is the allele frequency, $2f_l$ is the mean genotype value, and h is the function that gives the mean-variance relation for the untransformed phenotype distribution. We parameterize the model in terms of mean normalized genotypes, $(g - 2f_l)$, so that the h function is the same for all loci. When effects on the phenotypic mean are small and additive, there is an approximately linear relationship between the additive effect (α_l), the log-linear variance effect (α_{vl}), and the dispersion effect (d_l) at each locus l (Supplementary Note):

$$\alpha_{vl} \approx r_{av}\alpha_l + d_l,$$

It is possible to estimate r_{av} by regression of estimates of α_{vl} , $\hat{\alpha}_{vl}$, on estimates of α_l , $\hat{\alpha}_l$, across genome-wide loci (for all l). Standard regression estimates are downwardly biased due to noise in estimation of α_l , but this bias can be corrected (Methods). We show that (Supplementary Note)

$$r_{av} \approx \frac{\text{Cov}_l(\hat{\alpha}_{vl}, \hat{\alpha}_l)}{\text{Var}_l(\hat{\alpha}_l)} \left(1 + \frac{E_l[\text{Var}(\hat{\alpha}_l)]}{\text{Var}_l(\hat{\alpha}_l) - E_l[\text{Var}(\hat{\alpha}_l)]} \right),$$

where subscripts on Cov_l and Var_l indicate that expectations are to be taken over *loci*, whereas $\text{Var}(\hat{\alpha}_l)$ represents the within-locus sampling variance, which is known from the asymptotic distribution of the maximum likelihood estimator. The first factor, $\text{Cov}_l(\hat{\alpha}_{vl}, \hat{\alpha}_l)/\text{Var}_l(\hat{\alpha}_l)$, is the standard regression coefficient of $\hat{\alpha}_{vl}$ on $\hat{\alpha}_l$ across the loci, while the second term is an adjustment factor for the bias in the standard regression coefficient due to noise in estimation of α_l .

We use robust regression to estimate $\text{Cov}_l(\hat{\alpha}_{vl}, \hat{\alpha}_l)/\text{Var}_l(\hat{\alpha}_l)$ to prevent being overly influenced by outliers: specifically we use M-estimation³² with prior weights determined by $1/\text{Var}_l(\hat{\alpha}_l)$. To

estimate the adjustment factor, we use the sample estimates of $\text{Var}_l(\hat{\alpha}_l)$ and $E_l[\text{Var}(\hat{\alpha}_l)]$. We do not claim that this method is statistically optimal for estimation of r_{av} , but it worked well in simulations, suggesting the method is sufficient for large samples from a polygenic and heritable trait.

When many loci genome-wide are examined for a heritable and polygenic trait, error in estimation of r_{av} will be negligible and can be ignored. We thereby estimate dispersion effects by $\hat{d}_l = \hat{\alpha}_{vl} - r_{av}\hat{\alpha}_l$, which has a normal asymptotic sampling distribution (Supplementary Note):

$$\hat{d}_l \sim N(d_l, \text{Var}(\hat{\alpha}_{vl}) + r_{av}^2 \text{Var}(\hat{\alpha}_l)).$$

The heteroskedastic linear mixed model

The heteroskedastic linear mixed model (HLMM) is specified as

$$Y \sim N(X\alpha, h^2 GG^T + \exp(\text{diag}(V\beta))),$$

where G is a normalised $[N \times L]$ matrix of genotypes, and h^2 corresponds to the variance explained by the additive associations of the l genotypes in G . This differs from the standard linear mixed model due to the parameterised heteroskedasticity of the residual error term, $\exp(\text{diag}(V\beta))$. By modelling the effect of a test SNP on both the mean of the trait (putting it in X) and the residual variance of the trait (putting it in V), additive and log-linear variance effects of the SNP can be estimated, enabling the two-degree-of-freedom additive-variance test to be performed. Principal components and other covariates can also be included as both mean covariates (in X) and variance covariates (in V) (Supplementary Note).

Existing computational methods for fitting linear mixed models based on spectral decomposition³³, which are appropriate when $N \gg L$, do not work when the residual variance depends upon genotype. We develop an algorithm for efficient inference of the parameters of the heteroskedastic linear mixed model (HLMM) when the number of SNPs in the random effect is small compared to the sample size. The covariance matrix for the HLMM is

$$\Sigma = h^2 GG^T + D, \quad D = \exp(\text{diag}(V\beta)),$$

where G is a normalised $[N \times L]$ matrix of genotypes, and h^2 corresponds to the variance explained by the additive associations of the l genotypes in G . To compute the likelihood and gradient efficiently, we use low rank update formulae for the inverse and determinant of the covariance matrix:

$$\Sigma^{-1} = D^{-1} - h^2 D^{-1} G \Lambda^{-1} G^T D^{-1}; \quad \Lambda = I + h^2 G^T D^{-1} G.$$

Similarly, the log-determinant of Σ can be expressed as

$$\log|\Sigma| = \log|\Lambda| + \log|D|.$$

This allows us to rewrite the log-likelihood of the model as the log-likelihood of a diagonal system plus a low-rank correction. Let l be the log-likelihood of the model; then,

$$2l = -n\log(2\pi) - \log|D| - (y - X\alpha)^T D^{-1} (y - X\alpha) - \log|\Lambda| \\ + h^2 [G^T D^{-1} (y - X\alpha)]^T \Lambda^{-1} [G^T D^{-1} (y - X\alpha)],$$

which can be computed in $O(NL^2 + L^3)$ operations. The derivatives of the likelihood can be computed in the same complexity class, and we give expressions for these and further details of the algorithm implementation (Supplementary Note). We note the similarity to computational approaches previously used in general linear mixed models³⁴. The NL^2 term dominates when $N \gg L$, and this method has effectively the same scaling with sample size as methods based on spectral decomposition for additive association testing in a mixed model³³. However, our method requires an $O(NL^2)$ operation at every iteration, making it more computationally demanding than spectral decomposition, which requires only one $O(NL^2)$ operation. We benchmarked our algorithm for $N=100,000$ and $L=500$ on a 4.2GHz Intel Core i7 processor. Fitting one model took around 1.3 CPU-minutes, implying analysis of 400,000-800,000 SNPs would take between 9 and 17 hours on a server with 1000 cores.

Power Simulations

To test the power of the AV test relative to the additive test to detect a test locus G , we simulated phenotypes for 100,000 individuals according to the model:

$$Y|G = g \sim N(\alpha g, e^{\alpha_v g}),$$

where the genotype was simulated from a Binomial(2,0.5) distribution independently for each individual. The additive effect, α , varied such that the variance explained by the additive effect varied from 0% to 0.3%, and α_v varied from 0 to 0.05. For each pair (α, α_v) , 1000 independent phenotypes were simulated. We fitted models by maximum likelihood.

We also investigated how the association signals changed with sample sizes ranging from 10,000 to 100,000 for a fixed additive effect of $\alpha = 0.02$ (corresponding to a variance explained of 0.02%), with α_v varying from 0 to 0.05 in increments of 0.005.

To compare the power of different variance effect tests, we simulated phenotypes for 100,000 individuals according to the model:

$$Y|G = g \sim N(\alpha g, e^{\alpha_v g + \delta_v (g-1)^2}),$$

where δ_v represents the general variance effect and sets the deviation in log-variance of the heterozygote from a log-linear model. The genotype was simulated from a Binomial(2,0.5) distribution independently for 100,000 individuals. The additive effect, α , was set so that the variance explained was 0.02%, δ_v varied from 0 to 0.05, and α_v varied from 0 to 0.05. For each pair (δ_v, α_v) , 1000 independent phenotypes were simulated.

Simulation of non-normal phenotypes

We simulated phenotypes for 150,000 individuals from simulated ‘genomes’ of 22,000 independent SNPs. The frequency of each SNP was randomly sampled from a Uniform Distribution on [0.05,0.5], and each individual’s genotype was drawn independently from a Binomial distribution with probability parameter equal to the frequency. We randomly selected 1000 of 22,000 SNPs to have a causal effect on the phenotype. One of the 1000 SNPs was selected to have a dispersion effect, which we call G_1 . We generated an additive genetic component by sampling normally distributed effect sizes for the 999 causal SNPs other than G_1 . The SNP with the dispersion effect, G_1 , was given a positive additive effect scaled to explain 0.1% of the variance of the overall additive genetic component, which explained 10% of the phenotypic variance, and includes the additive effects of all 1000 causal SNPs including G_1 . The overall additive genetic component was scaled to have mean zero and variance one.

To simulate non-normal phenotypes, we used a Gamma model. If Y has Gamma distribution with shape parameter (k) and scale parameter (θ), then $Y \sim \text{Gamma}(k, \theta)$. We parameterize each individual's distribution to give a certain heritability for the trait and dispersion effect of d_1 to SNP G_1 . Each individual's phenotype, Y_i , was drawn from a Gamma Distribution with parameters chosen so that

$$E[Y_i] = \mu + A_i,$$

where A_i is the value of the additive genetic component of individual i ; and, for some $s > 0$,

$$\text{Var}[Y_i] = s(\mu + A_i) \exp(d_1(g_{i1} - f_1)) = sE[Y_i] \exp(d_1(g_{i1} - f_1)),$$

where g_{i1} is the genotype of individual i for G_1 . This shows the linear relation between the conditional means and conditional variances of a Gamma distributed phenotype. This implies that, by the Law of Total Variance,

$$\text{Var}(Y) \approx \mu s + 1.$$

This implies that the heritability, h^2 , is $h^2 \approx (\mu s + 1)^{-1}$. For a given μ and h^2 , one can solve for s . We chose $h^2 = 0.1$ and $\mu = 5$ for our simulations, implying $s = 1.8$. To achieve this, each individual's phenotype is drawn from a Gamma Distribution, $Y_i \sim \text{Gamma}(k_i, \theta_i)$, with

$$k_i = \exp(-d_1(g_{i1} - f_1))(\mu + A_i)/s,$$

$$\theta_i = s \exp(d_1(g_{i1} - f_1)).$$

The phenotypes simulated in this way were inverse-normally transformed before fitting models.

UK Biobank data

We used genotype data from the UK Biobank Project. Quality control is described in the UK Biobank genotyping QC document²⁰. We used the sample of 409,703 individuals identified as having predominantly white British ancestry by UK Biobank. We then excluded individuals from the analysis that had been flagged as having a putative sex chromosome aneuploidy, excess relatives, or excess heterozygosity by the UK Biobank. See also the Life Sciences Reporting Summary.

Relatedness was determined by UK Biobank²⁰. We split the sample into two groups: one without any pair related at the third-degree level or higher, and its complement. The final 'related' sample had 131,835 individuals and the final 'unrelated' sample had 276,415 individuals.

Analysis of BMI

An inverse normal transformation was applied to BMI. For mean and variance covariates, we used age (Data-Field 21022), sex (Data-Field 31), age², age³, age x sex, age² x sex, age³ x sex, genotyping array, and the 40 principal components provided by UK Biobank²⁰. Throughout our analysis of BMI, we only consider SNPs with minor allele frequency greater than 5% and missingness less than 5%.

To choose the SNPs for the random effect in each sample, we ranked the SNPs by their negative-log p-values for additive effects from fitting the model *without* the random effect. The advantages of selecting SNPs in this way have been elucidated³⁵, although there may be disadvantages compared to using a full-rank random effect when there is family relatedness¹⁹.

For the unrelated subsample, we selected 500 SNPs from the ranked list in descending order, only adding a SNP if it had an $r^2 < 0.1$ with all previously added loci. For the related sample, we also first fit the model without random effects and ranked SNPs by strength of evidence for an additive effect on BMI. We selected 1000 SNPs from this list in descending order, only adding a SNP if it had minor allele frequency (MAF) greater than 0.4 and had $r^2 < 0.01$ with all previously added loci (Methods). We used a more stringent r^2 threshold for the related sample to ensure loci were independent, and thus together gave a better estimate of relatedness than if we had included loci in linkage disequilibrium. We selected a greater number of common, independent loci for the related sample in order to better control for the relatedness present. To fit the mixed model, we fit the model including the random effects for the selected loci other than the loci on the same chromosome as the test SNP.

For computational efficiency, we first fitted a null model for each chromosome with all of the mean and variance covariates, obtaining $\widehat{\alpha}_0$ and $\widehat{\beta}_0$ as the maximum likelihood estimates of α and β . We then performed the transformation

$$Y \rightarrow \text{diag}(\exp(-0.5V\widehat{\beta}_0))(Y - X\widehat{\alpha}_0)$$

to remove the influence of known covariates on the mean and the residual variance.

We combined additive effects across the two subsamples in a fixed-effects meta-analysis. We did the same for log-linear variance effects. We calculated Wald statistics for additive and log-linear variance effects by taking the square of the ratio of the estimated effects and their standard errors. The Wald statistic is asymptotically equivalent to a log-likelihood ratio. For the additive test statistics, we used LD-score regression³¹ to infer an inflation factor (see URLs for

source of LD scores). For the log-linear variance test statistics, we calculated the sample median across all test SNPs and took the ratio of the sample median to 0.456 as an inflation factor³⁶. We formed two degree of freedom tests for each SNP as the sum of the inflation adjusted chi-squared test statistics for additive and log-linear variance effects.

To estimate r_{av} , we used the procedure outlined above for all SNPs excluding those on chromosome 6. We excluded SNPs on chromosome 6 in order to exclude SNPs in the MHC region, many of which show evidence for additive and log-linear variance effects. We then calculated Wald statistics for dispersion effects and took the ratio of the sample median to 0.456 as an inflation factor³⁶.

We pruned the list of SNPs that were genome-wide significant under either the additive or AV tests to ensure that our results did not include SNPs in linkage-disequilibrium with SNPs with stronger additive associations. For each chromosome, we took the SNP with the strongest additive association first, and we added SNPs in order of additive association strength, excluding those with $r^2 > 0.01$ with a SNP already chosen. We did this to ensure that any locus we identified as having a dispersion effect was independent from other loci with strong additive effects.

If a SNP exhibits a dominance effect, it could lead to spurious inference of a log-linear variance and/or dispersion effect under the AV model. By fitting a model that also included dominance effects, we found no evidence that the estimated log-linear variance effects of the SNPs in Table 1 were driven by dominance effects (Supplementary Table 5).

Gene-by-environment interaction analysis

We used a previously published model for testing for interactions between rs1421085 (*FTO*) and various lifestyle and environmental factors²⁹. In this model, the SNP and its interactions with multiple lifestyle and environmental factors are fit jointly. Furthermore, because the UK Biobank contains many correlated measures of diet and physical activity, these variables were collapsed into diet and activity ‘scores’. In brief, each activity and diet variable is weighted by its strength and direction of association with BMI to create a score that predicts BMI well from measures in a particular category (diet or physical activity). We used the same weights for construction of these scores as in a previous analysis of rs1421085²⁹.

The lifestyle and environmental variables used are as described in the previous analysis of rs1421085 (*FTO*)²⁹. We mean-imputed missing observations of the lifestyle and environmental

variables. For mean and variance covariates, the test SNP, age, sex, age², age³, age x sex, age² x sex, age³ x sex, genotyping array, and the 40 principal components provided by UK Biobank²⁰ were used. In addition to these covariates, the lifestyle and environment variables and their interaction with the test SNP were also used as mean covariates. We fitted the models in the combined sample comprised of both the related and unrelated subsamples. To help control for relatedness and confounding, we modelled random effects for the 1,000 SNPs selected for the analysis of the related sample, excluding those SNPs on the same chromosome as the test SNP.

Diabetes and rs1801282

To test for an interaction between rs1801282 and diabetes status, we used data field 2443 ('diabetes diagnosed by doctor'). We removed those who answered 'Do not know' and 'Prefer not to answer'. For mean and variance covariates, rs1801282 genotype, age, sex, age², age³, age x sex, age² x sex, age³ x sex, genotyping array, and the 40 principal components provided by UK Biobank²⁰ were used. In addition to these covariates, 'diabetes diagnosed by doctor' and its interaction with rs1801282 were also used as mean covariates.

Birth weight and rs900400

If rs900400 affects BMI variability through birth weight, then fitting birth weight and rs900400 jointly should reduce the estimated variance effect of rs900400. To test this, we used self-reported birth weight (Data Field 20022), available for 230,477 genotyped participants without missing calls for rs900400. For mean and variance covariates, we used rs900400 genotype, birth weight, age, sex, age², age³, age x sex, age² x sex, age³ x sex, genotyping array, and the 40 principal components provided by UK Biobank²⁰. The estimated log-linear variance effect of rs900400 in this model was 0.0186 (S.E. = 0.0043). After dropping birth weight from the model, the estimated log-linear variance effect of rs900400 in the same sample was 0.0181. The increase in the variance effect when fitting rs900400 jointly with birth weight may be due to the fact that higher birth weight is associated with decreased variability of BMI ($p=9.0 \times 10^{-9}$, two-sided Z-test), whereas the birth weight increasing allele of rs900400 is associated with increased BMI variability. This implies that the birth weight effect of rs900400 could be masking its effect, independent of birth weight, on BMI variability. This is in direct contradiction to the hypothesis that the effect of rs900400 on BMI variability is due to rs900400's effect on birth weight.

Variance effects of Leptin SNPs

We took summary statistics from a genome-wide association study of circulating leptin levels adjusted for BMI³⁰. (As higher BMI is associated with higher leptin levels, this analysis looks for SNPs that affect leptin levels through pathways other than BMI.) We took the intersection of the SNPs from the leptin study with the SNPs on the UK Biobank array. We constructed a list of 100 SNPs at approximately independent loci with evidence for association with leptin. We added SNPs to our list in order of negative log p-value for a leptin effect. To ensure the SNPs in our list were approximately independent of each other, we only added a SNP to the list if it had $r^2 < 0.1$ with all the SNPs already in the list. To estimate the expected dispersion effect per unit increase in leptin effect, we used the same kind of procedure we used for estimation of the mean-variance relation parameter, r_{av} (see above): we used robust regression (M-estimation) with weights equal to the inverse of the sample variance of the dispersion effect, and we adjusted the regression coefficient for downward bias due to noise in the estimation of the leptin effects.

As a check, we performed an analogous analysis for the top 100 lead SNPs from independent loci for leptin adjusted for BMI and regressed their additive effects for BMI on their effects for leptin adjusted for BMI. As expected (because the leptin levels have already been adjusted for BMI) we saw no significant effect ($p = 0.47$).

Methods-only References

31. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
32. Marazzi, A. *Algorithms, Routines, and S-Functions for Robust Statistics*. (Taylor & Francis, 1993).
33. Lippert, C. *et al.* FaST linear mixed models for genome-wide association studies. *Nat. Methods* **8**, 833–5 (2011).
34. Wolfinger, R., Tobias, R., Sall, J., Tobias, R. & Sall, J. Computing Gaussian Likelihoods and Their Derivatives for General Linear Mixed Models. *SIAM J. Sci. Comput.* **15**, 1294–1310 (1994).
35. Lippert, C. *et al.* The benefits of selecting phenotype-specific variants for applications of mixed models in genomics. *Sci. Rep.* **3**, 1815 (2013).
36. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004 (1999).